The trial will investigate the influence of hepatic function on the PK of gemigliptin. In an additional treatment period, the PK and safety of multiple dosing of gemigliptin in healthy White subjects will be investigated.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
28
Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
CRS Clinical Research Services
Kiel, Schleswig-Holstein, Germany
AUC
Blood samples will be prepared at planed points.
Time frame: Several time points until 72hr
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.